Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Friedlaender

Showing results (11-20 of 106) with videos related to

Pageof 11
Sort By:
ESMO Open|July 6, 2019
New emerging targets in cancer immunotherapy: the role of TIM3Alex Friedlaender, Alfredo Addeo, Giuseppe Banna
Cancers|June 2, 2021
KRAS G12C Mutations in NSCLC: From Target to ResistanceAlfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
Translational Lung Cancer Research|August 14, 2023
Tarlatamab: a potential new option for recurrent small cell lung cancerAlfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2020
Filtering Data About Treatment-Induced Renal Injury: From Biology to PracticeAlfredo Addeo, Luigi Giuseppe Banna, Alex Friedlaender
BMJ Evidence-Based Medicine|July 11, 2020
Is clinical effectiveness in the eye of the beholder during the COVID-19 pandemic?José Luis Sandoval, Alex Friedlaender, Alfredo Addeo
Journal for Immunotherapy of Cancer|September 5, 2020
Tracking the tailAlex Friedlaender, Stephen V Liu, Alfredo Addeo
The Oncologist|December 14, 2020
ADAURA: Mature Enough for Publication, Not for Prime TimeAlfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
Translational Cancer Research|February 4, 2022
Stepping in the right direction but still some ways to goAlfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
Frontiers in Oncology|May 6, 2022
The Landscape of Immunotherapy Resistance in NSCLCDaniele Frisone, Alex Friedlaender, Alfredo Addeo, et al.
World Journal of Clinical Oncology|May 7, 2021
Oncogenic driver mutations in non-small cell lung cancer: Past, present and futureMathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, et al.
Pageof 11

Showing results (11-20 of 106) with videos related to

Sort By:
Pageof 11
ESMO Open|July 6, 2019
New emerging targets in cancer immunotherapy: the role of TIM3Alex Friedlaender, Alfredo Addeo, Giuseppe Banna
Cancers|June 2, 2021
KRAS G12C Mutations in NSCLC: From Target to ResistanceAlfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
Translational Lung Cancer Research|August 14, 2023
Tarlatamab: a potential new option for recurrent small cell lung cancerAlfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2020
Filtering Data About Treatment-Induced Renal Injury: From Biology to PracticeAlfredo Addeo, Luigi Giuseppe Banna, Alex Friedlaender
BMJ Evidence-Based Medicine|July 11, 2020
Is clinical effectiveness in the eye of the beholder during the COVID-19 pandemic?José Luis Sandoval, Alex Friedlaender, Alfredo Addeo
Journal for Immunotherapy of Cancer|September 5, 2020
Tracking the tailAlex Friedlaender, Stephen V Liu, Alfredo Addeo
The Oncologist|December 14, 2020
ADAURA: Mature Enough for Publication, Not for Prime TimeAlfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
Translational Cancer Research|February 4, 2022
Stepping in the right direction but still some ways to goAlfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
Frontiers in Oncology|May 6, 2022
The Landscape of Immunotherapy Resistance in NSCLCDaniele Frisone, Alex Friedlaender, Alfredo Addeo, et al.
World Journal of Clinical Oncology|May 7, 2021
Oncogenic driver mutations in non-small cell lung cancer: Past, present and futureMathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, et al.
Pageof 11